Myoma morcellation and leiomyosarcoma panic

Source: Gynecological Surgery - Category: OBGYN Source Type: research

Related Links:

Abstract Uterine smooth muscle tumors of unknown malignant potential [STUMP]s are neoplasms with pathological features that preclude an equivocal diagnosis of leiomyosarcoma, but that do not fulfill the criteria for leiomyoma or its variants, and raise concerns that the tumors may behave in a malign fashion. Total hysterectomy with or without bilateral salpingo-oophorectomy is the standard treatment if fertility is completed, whereas myomectomy alone can be taken into consideration in young patients who desire to preserve childbearing potential. A careful surveillance every 6 months for 5 years and then yearly...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Conclusion: This population-based study was the first report of epidemiology of sarcomas in Shanghai according to anatomic site and histologic type. The diversity and rarity of sarcomas suggested more detailed data are warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion.Although overall survival of patients with STS with synchronous metastases in this nationwide and “real‐life” population has improved over the years, the improvement was not statistically significant, despite new treatment options.Implications for Practice.Treatment of patients with metastatic soft tissue sarcoma (STS) has changed in the past years, with new drugs such as trabectedin (2007) and pazopanib (2012) becoming available. By using data from the nationwide Netherlands Cancer Registry, the impact of these changes in treatment policies on survival is analyzed in a “real‐life” po...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Sarcomas, European Perspectives Source Type: research
Conclusion.Conditional survival estimates show clinically relevant variations according to time since first diagnosis in both young and elderly patients with STS. These results can help STS survivors adjust their view of the future and STS care providers plan patient follow‐up.Implications for Practice.For patients with sarcoma who are followed up years after being treated for their disease, a common scenario is for the patient and caregivers to ask practitioners what the longer‐term prognosis may be. The question posed to practitioners may be, “Doc, am I now cured? It's been 5 years since we finished treatment.&...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Sarcomas Source Type: research
AbstractBackground.Soft‐tissue sarcomas (STS) describe a heterogeneous group of mesenchymal tumors with limited treatment options. Targeted therapies exist for BRCA1/2 gene alterations, but their prevalence and role have not been fully described in STS. Here, we present the largest effort to characterize the frequency of homologous recombination (HR) DNA repair pathway alterations in STS subtypes and highlight the unique nature of leiomyosarcoma (LMS).Materials and Methods.DNA sequencing data were analyzed for HR pathway alterations for 1,236 patients with STS. DNA sequencing data from an additional 1,312 patients were u...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Sarcomas, Precision Medicine Clinic: Molecular Tumor Board Source Type: research
Publication date: May–June 2019Source: Journal of Clinical and Experimental Hepatology, Volume 9, Issue 3Author(s): K. Elankumaran, Sri Aurobindo Prasad Das, R. Anand, Anand Khakhar, V. Rochita, C. Vasantharoopan, K. Madankumar, V. Balaji
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
CONCLUSION: AC, including gemcitabine/docetaxel regimen, or AR did not reduce the recurrence rate in patients with early-stage uLMS. PMID: 31307664 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Conclusions: The strongest predictors of disease-free and overall survival are tumor-specific characteristics, while surgical factors are less impactful. Nonsurgical therapies are not associated with improved outcomes despite persistent interest and utilization. Complete macroscopic resection (R0/R1) remains a persistent potentially modifiable risk factor associated with improved overall survival in patients with retroperitoneal sarcomas. PMID: 31281208 [PubMed]
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Authors: Verboom MC, Gelderblom H, Kerst JM, Steeghs N, Reyners AKL, Sleijfer S, van der Graaf WTA, van den Hout WB Abstract Trabectedin and ifosfamide are among the few cytostatic agents active in advanced soft tissue sarcomas (STSs). Trabectedin is most potent against so-called L-sarcomas (leiomyosarcoma and liposarcoma). The survival gain and cost-effectiveness of these agents in a second-line setting were analysed in the setting of advanced STS after failure of anthracyclines. A prospective observational trial had previously been performed to assess the use of trabectedin in a Dutch real-world setting. Data on ...
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Abstract Leiomyosarcomas are rare, aggressive tumors, which exhibit a poor prognosis regardless of stage. Pre-operative diagnosis can be difficult as leiomyosarcoma can mimic features of the more common, benign uterine leiomyoma. The goal of this study was to identify specific molecular markers to discriminate between uterine leiomyosarcomas and leiomyomas to facilitate timely, accurate diagnosis and treatment. Gene expression profiles of three leiomyosarcomas, leiomyomas, and normal myometrial tissue samples were analyzed using the Affymetrix Human Gene 1.0 ST Array. GC-robust multiarray average calculation and A...
Source: Experimental and Molecular Pathology - Category: Pathology Authors: Tags: Exp Mol Pathol Source Type: research
More News: Leiomyosarcoma | OBGYN